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Abstract
Background Patients with rectal cancer who present with sarcopenia (low muscle mass) are at significantly greater risk of 
postoperative complications and reduction in disease-free survival. We performed a subanalysis of a randomised controlled 
study [the REx trial; www.isrct n.com; 62859294] to assess the potential of prehabilitation to modify muscle mass in patients 
having neoadjuvant chemoradiotherapy (NACRT).
Methods Patients scheduled for NACRT, then potentially curative surgery (August 2014–March 2016) had baseline physi-
cal assessment and psoas muscle mass measurement (total psoas index using computed tomography-based measurements). 
Participants were randomised to either the intervention (13–17-week telephone-guided graduated walking programme) or 
control group (standard care). Follow-up testing was performed 1–2 weeks before surgery.
Results The 44 patients had a mean age of 66.8 years (SD 9.6) and were male (64%); white (98%); American Society of 
Anesthesiologists class 2 (66%); co-morbid (58%); overweight (72%) (body mass index ≥ 25 kg/m2). At baseline, 14% 
were sarcopenic. At follow-up, 13 (65%) of patients in the prehabilitation group had increased muscle mass versus 7 (35%) 
that experienced a decrease. Conversely, 16 (67%) controls experienced a decrease in muscle mass and 8 (33%) showed an 
increase. An adjusted linear regression model estimated a mean treatment difference in Total Psoas Index of 40.2mm2/m2 
(95% CI − 3.4 to 83.7) between groups in change from baseline (p = 0.07).
Conclusions Prehabilitation improved muscle mass in patients with rectal cancer who had NACRT. These results need to be 
explored in a larger trial to determine if the poorer short- and long-term patient outcomes associated with low muscle mass 
can be minimised by prehabilitation.
Keywords Prehabilitation · Muscle wasting · Rectal cancer · Sarcopenia · Neoadjuvant chemoradiotherapy · Sarcopenia · 
Neoadjuvant therapy · Rectal neoplasms · Preoperative care · Walking
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Introduction
Low muscle mass, or sarcopenia, has been reported in up 
to 60% of patients with colorectal cancer either at the time 
of diagnosis, or as a result of neoadjuvant chemoradiother-
apy (NACRT) [1–4]. If present, the patient is at higher risk 
of worse outcomes following surgical resection, includ-
ing major complications, increased hospital stay and early 
postoperative mortality [5, 6]. Sarcopenia also appears 
to influence a patient’s long-term outcome with reduced 
1- and 5-year survival in patients with colorectal cancer 
reported [7, 8]. These poorer outcomes are not restricted 
to patients with rectal cancer and have been extensively 
reported in other malignancies including, renal, lung and 
gastroesophageal [9–12]. However, to date, there are no 
reported interventions that have modified or offset treat-
ment-related sarcopenia in these cancer populations.
Prehabilitation is an intervention that places emphasis 
on optimising patients prior to their first treatment and 
consists predominately of individualised physical activity 
or exercise programmes. Shown to be safe and feasible in 
many cancer populations, prehabilitation studies are now 
reporting on improved patient outcomes after surgery 
[13–22]. With physical activity and exercise providing 
physiological overload that increases muscle mass in the 
general population, prehabilitation in patients with rectal 
cancer provides an opportunity to determine if low muscle 
mass can be modified.
Within a study that aimed to assess the feasibility of 
performing a physical activity intervention during NACRT 
for rectal cancer, we performed a subanalysis to establish 
the prevalence of sarcopenia and to determine if a physical 
activity intervention had the potential to modify muscle 
mass.
Materials and methods
Study design and data collection
From August 2014 to March 2016 (20 months), any adult 
over 18 years with a new diagnosis of rectal cancer where 
NACRT was planned was considered for inclusion in the 
REx trial [23]. The trial was approved by the West of Scot-
land Research Ethics Service (14/WS/0079) and registered 
with ISRCTN (www.isrct n.com; 62859294; 17th March 
2014). This study was funded by the Chief Scientist Office 
(CZH/4/986; www.cso.scot.nhs.uk).
This was a two-arm randomised controlled feasibility 
study (RCT) with the full protocol, physical intervention 
and results published [23]. Briefly, each participant’s 
demographics were recorded and they completed baseline-
testing including daily step count, physical parameters and 
psychological. Clinico-pathological outcomes were also 
recorded. Baseline testing was pre-intervention (Test 1 
prior to undergoing NACRT) and repeated post-interven-
tion (1–2 weeks pre-surgery, post-prehabilitation, Test 2).
The walking programme started prior to NACRT and was 
of minimum 13-week duration. It consisted of graduated 
step count goals using pedometers and was telephone guided 
supplemented by walking diaries. The target was for the par-
ticipants to increase their average daily step count by 3000 
accumulated above their baseline by week 8 [24–28]. The 
control group received standard care and told to maintain 
their normal level of physical activity.
Body composition measurement
Muscle mass was measured on each patient using a validated 
technique: the total cross-sectional area of the psoas muscles 
[total psoas area, (TPA)] [8]. This was measured manually 
using a free-hand drawing technique on Picture Archiving 
and Communication System (PACS) at the level of the L3 
vertebra on pre-treatment computed tomography (CT) scan. 
To ensure standardisation, the exact level of measurement 
was defined as the CT slice in which both transverse pro-
cesses were maximally in view. The outline of each indi-
vidual psoas muscle was traced, the area of each calculated, 
and summated to provide the TPA  (mm2). The TPA was 
then standardised for patient height using the formula TPA 
 (mm2)/height  (m2) to provide the total psoas index (TPI) 
for each patient. TPI was calculated pre-NACRT and post-
NACRT within 4 weeks of planned surgery.
The threshold values used for the diagnosis of sarcopenia 
were: TPI less than 524  mm2/m2 for males, and 385  mm2/
m2 for females [29]. To ensure the reliability of our tech-
nique, 20 scans were randomly selected and measured for 
sarcopenia by blinded trained investigators to allow calcula-
tion of inter- and intra-class correlation coefficients (ICC). 
The ICC (r2) values for inter- and intra-class reliability were 
0.957 and 0.985, respectively (close to 1 indicates excellent 
agreement).
Statistical analysis
The Mann–Whitney test was used to test for a difference in 
median change from baseline in TPI between study groups, 
while the chi-squared test was used to compare the equiva-
lent categorical variable defining sarcopenia (level of sig-
nificance p < 0.050). A linear regression model was fitted 
to the change from baseline in TPI to assess its association 
with the study group while adjusting for baseline variables. 
Spearman’s correlation coefficient was calculated to assess 
the association between change in TPI and step count. No 
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hypothesis tests were carried out for this part of the analysis 
due to small numbers. All statistical analysis were under-
taken using R (version 3.5.0) [30].
Results
Baseline participant characteristics
A total of 48 patients (n = 24 in each group) were recruited 
to the study, of which 44 underwent follow-up CT staging 
(the 4 who did not were all in the intervention group). The 
44 patients had a mean age of 66.8 years (SD 9.6). The 
majority were male (64%), white (98%), American Society 
of Anesthesiologists (ASA) class 2 (66%) and co-morbid 
(58%). Most (59%) participants currently or had previously 
smoked, 86% reported current alcohol consumption and 72% 
were overweight (body mass index (BMI) ≥ 25 kg/m2) with 
20% obese (BMI ≥ 30 kg/m2).
Overall, 6 (n = 14%) of the 44 patients were sarcopenic at 
baseline: intervention group 4 (20%) versus control group 
2 (8%). Median baseline TPI in the intervention group was 
583.5mm2/m2, and in the control 593.3mm2/m2 (Table 1).
None of the 44 participants achieved the recommended 
government activity guidelines at baseline. The mean num-
ber of steps per day of all participants was 6248 (range 
1151–17,422 steps) leading to 54% classified as sedentary 
or only slightly active (Table 1).
Follow‑up results: step count
Median walking intervention duration was 14 weeks (IQR 
13–17). At follow-up testing, both groups recorded a reduc-
tion in daily step count, with the control group showing a 
larger reduction (difference between groups in change from 
baseline of 785 [95% CI − 1194, 2765] adjusted for baseline 
median daily step count, age and sex). A higher percentage 
of the intervention group achieved step count improvements 
at 12 weeks (23.5% versus 15.8%) [19].
Follow‑up results: muscle mass measurement
The intervention group showed a median increase in TPI of 
16.0  mm2/m2 to a median TPI of 624.2mm2/m2, compared 
to a decrease of 8.4mm2/m2 in the control group to a median 
TPI of 571.2mm2/m2 (group difference in median change 
from baseline of 24.4  mm2/m2, p = 0.07) (Fig. 1). Figure 2 
displays the scatter plots for TPI showing that 13 (65%) of 
patients in the prehabilitation group experienced an increase 
in muscle mass, versus 7 (35%) that experienced an overall 
decrease, while 16 (67%) controls experienced a decrease 
and 8 (33%) showed an increase (p = 0.07).
A linear regression model adjusting for age, any comor-
bidities and baseline TPI estimated a mean treatment dif-
ference of 40.2mm2/m2 (95% CI − 3.4 to 83.7) between the 
intervention and control groups in change from baseline 
(p = 0.07).
Table 1  Comparison of baseline physical measurements of REx trial participants: Intervention group versus control group, for patients with 
muscle mass measurements
TPI Total Psoas Index
a Expressed as thousands
All (N = 44) Intervention (N = 20) Control (N = 24)
Mean TPI  mm2/m2 (SD) 598 (161) 585 (152) 608 (171)
Median TPI  mm2/m2 (IQR) 584 (460–707) 584 (450–650) 593 (460–718)
Sarcopenic
 No 38 (86%) 16 (80%) 22 (92%)
 Yes 6 (14%) 4 (20%) 2 (8%)
Median steps per  daya(IQR) 6.2 (5.1–10.1) 6.1 (4.7–9.2) 6.7 (5.7–10.3)
Sedentary 10 (23%) 6 (30%) 4 (17%)
Slightly active 13 (30%) 5 (25%) 8 (35%)
Moderately active 16 (37%) 7 (35%) 9 (39%)
Very active 4 (9%) 2 (10%) 2 (9%)
Sit-to-stand test, no. completed in 30 s [mean (SD)] 11.5 (2.7) 11.6 (2.4) 11.4 (3.0)
6-Min walking tests, metres [mean (SD)] 441.3 (63.9) 446.9 (61.9) 436.7 (66.4)
% of week spent active [mean (SD)] 6.6 (2.8) 6.5 (2.9) 6.7 (2.9)
% of week spent sedentary [mean (SD)] 75.9 (12.1) 76.9 (6.1) 74.9 (15.6)
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Discussion
This is the first study to report modification of muscle 
mass with prehabilitation in patients with colorectal can-
cer who had neoadjuvant therapy. The graduated indi-
vidualised walking programme provided sufficient mus-
cle overload to increase psoas muscle mass in 65% of the 
intervention group in comparison to the controls where 
67% had the expected reduction in muscle mass as a con-
sequence of having long-course chemoradiotherapy. With 
14% of patients presenting with sarcopenia at diagnosis, 
prehabilitation may have a further role to play in the perio-
perative pathway.
Body composition has increasingly been recognised as 
having an influencing prognostic role in colorectal cancer 
[5–8, 31]. Despite being modifiable, in contrast to pathologi-
cal staging, there are few reported interventions to modify 
muscle mass and potentially improve patient outcomes in the 
surgical setting [32]. Furthermore, it is not routine practice 
to screen for low muscle mass and the results from this study 
show that other physical measurements (daily step count, 
6MWT, STS) are not directly related to muscle mass. In 
particular, BMI is limited as the typical physical appearance 
of a patient with newly diagnosed colorectal cancer is chang-
ing with cancer cachexia becoming increasingly infrequent. 
This is likely to reflect both the introduction of the NHS 
Bowel Screening Programme detecting cancers at an earlier 
stage and of societal behavioural changes in diet and physi-
cal activity [33].
Evidence for screening and successful physical activity 
interventions comes from the gerontology literature where 
sarcopenia or low muscle mass has been associated with 
ageing. Prevention or treatment of this muscle mass reduc-
tion has been seen as key to enabling older adults to maintain 
their quality of life and minimise physical limitations [34]. 
Two recent reviews assessed various forms of exercise in 
older adults and concluded that resistance training had a 
lead role in optimising muscle mass and walking capacity 
[35, 36].
There are several proposed mechanisms for the relation-
ship between low muscle mass and colorectal cancer out-
comes. First, it could be that exercise simply provides suf-
ficient physiological overload to improve muscle mass and, 
therefore, improve mobility as the patient goes through their 
treatment, minimising cardiorespiratory complications. Step 
count per se does not appear to relate to psoas muscle mass 
perhaps because it does not measure intensity and alterna-
tive physical capacity measurements could be considered 
to explore this relationship such as dynamometry. Second, 
systemic inflammation as a host response to the underlying 
rectal malignancy has been shown to result in low muscle 
mass [37]. Third, observational data have consistently shown 
that patients who are more physically active improve their 
cancer-specific survival leading to the hypothesis that exer-
cise could have an anti-tumour strategy requiring a precision 
oncology approach [33, 38]. Finally, the gut microbiome 
could be a link; alterations in its composition could reduce 
chronic inflammation and anabolic resistance, leading to an 
increased muscle mass [39].
Prehabilitation prior to surgery provides an excellent 
opportunity to modify muscle mass. With an increasing 
number of publications supporting its feasibility in the colo-
rectal cancer setting, accompanied by increases in aerobic 
Fig. 1  Comparison of change in psoas muscle mass  (mm2/m2) after 
physical intervention in patients with rectal cancer undergoing chem-
oradiotherapy. TPI = Total Psoas Index
Fig. 2  Scatterplots showing Total Psoas Index (TPI) measurements 
 (mm2/m2) before and after the study period plus change from baseline 
in patients undergoing neoadjuvant chemoradiotherapy for rectal can-
cer. The dotted lines represent zero change
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capacity and potentially a reduction in complications, the 
perioperative care pathway is changing [13–22]. The com-
ponents of prehabilitation vary between studies with an ini-
tial focus on increasing aerobic capacity now expanding to 
consider psychological and dietary interventions alongside 
resistance training as stated in the recent Macmillan Preha-
bilitation Evidence and Insight Review [40]. There is still 
much work to be done in identifying the optimal prehabili-
tation pathway for each individual patient, including what 
components constitute their prehabilitation, what duration 
and intensity and in what setting: hospital, community and 
self-led.
There are strengths to this study. We prospectively 
recruited a population that is often under-reported in 
research studies, but one that reflects many current surgi-
cal practices: older, co-morbid, predominately sedentary, 
deprived and overweight. With 83% of these participants 
completing the prehabilitation study, this population should 
not be excluded from future work. In addition, muscle mass 
measurement was shown to be a valid, simple and reproduc-
ible technique that could be integrated into the NHS with 
minimal costs.
The authors acknowledge limitations. This was an 
unplanned subanalysis of a feasibility study so the reader 
must be cautious about making inferences about the reported 
outcomes due to very small numbers. In addition, selection 
bias cannot be excluded with motivated patients potentially 
more likely to participate and, therefore, achieve better 
results.
Conclusions
Patients with rectal cancer presenting with low muscle mass 
and those developing it as a result of NACRT have poorer 
short- and long-term patient outcomes as a consequence. 
This study tentatively reports that a targeted individualised 
physical activity intervention (prehabilitation) may increase 
muscle mass and offset the expected reduction with NACRT. 
This novel work needs to be explored in a larger trial setting 
to determine the influence of prehabilitation on short- and 
long-term patient outcomes.
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